News

It’s been an extraordinary week for HIV science. An extraordinary week for the HIV response. As 6,000 researchers, advocates, policy makers, funders and community leaders begin their journeys home from the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris, here’s a quick summary of some of what made news inside the Palais des Congrès this past week and got news editors around the world talking too:1. The future is injectable, as treatment for HIV and...

Innovative approaches in cancer therapy point to new avenues for HIV cure research
(Paris, France) -- Emerging opportunities to cure or achieve the long-term remission of HIV infection will be the focus when scientists, advocates and funders gather for the International AIDS Society (IAS) HIV Cure & Cancer Forum on 22 and 23 July, just before the 9th IAS Conference on HIV Science (IAS 2017).

This year's late-breaking HIV science has been added to the online programme for the 9th IAS Conference on HIV Science (IAS 2017). Take a look at the full programme, now updated with all accepted abstracts, satellite symposia and more. New scientific highlights include: Findings on safety, tolerability and pharmacokinetics of long-acting, injectable pre-exposure prophylaxis (PrEP) Interim data on the efficacy of a dolutegravir-based regimen as a second-line treatment in a resource-limit...

The 9th IAS Conference on HIV Science (IAS 2017) will showcase the latest developments in HIV prevention science, including PrEP on demand, community-based testing, and strategies to meet the needs of key populations affected by HIV. Scientific highlights include: New analysis of the IPERGAY trial, evaluating PrEP on demand among men who have sex with men less frequently or who engage in “chemsex” Estimates of time of infection to determine whether migrants are acquiring HIV bef...

The 9th IAS Conference on HIV Science (IAS 2017) is going back to basics, with the largest-ever selection of abstracts from the field of basic science. This year we return to Paris, the city renowned for the co-discovery of HIV and pioneering scientific research. Highlights will include: New understanding from a novel barcoded virus of how the latent HIV reservoir is reactivated following treatment interruption Implications from a study of a subset of elite controll...

More than 18 million people worldwide are accessing HIV treatment, and new World Health Organization (WHO) guidelines have dramatically expanded the number of people eligible to start treatment in many countries.The 9th IAS Conference on HIV Science (IAS 2017) will showcase the latest innovations to meet the increased need for HIV care in a way that is both clinically effective and cost effective. Scientific highlights include: 96-week results from MOBIDIP trial: Safety and efficacy of...

The IAS Conference on HIV Science is the largest open scientific conference on HIV and AIDS related issues, boasting a best-in-class scientific programme.In addition to a strong abstract-driven programme, IAS 2017 will offer symposia, workshops and interactive sessions developed by an international committee of HIV scientists and professionals.Here is a first glimpse of what you can expect in Paris, which you can browse in our preview of the conference programme:Understanding HIV pathogenes...

HIV experts gather in Paris this July - Today, the International AIDS Society (IAS) announced the plenary speakers and programme for the 9th IAS Conference on HIV Science (IAS 2017). Hosted in partnership with ANRS (The French National Agency for Research on AIDS and Viral Hepatitis), the conference will take place from 23-26 July 2017 in Paris, France.